• Indication
    • Uveitis (macular edema associated with uveitis)

      Diabetic Macular Edema

    • Progressive Myopia

    • Presbyopia

    • Mydriasis

    • Corneal endothelial dysfunction

    • Dry Eye

    • Glaucoma

  • Commercial Rights
    • Greater China, South Korea, ASEAN countries, India, Australia, New Zealand

    • Greater China & South Korea

    • Greater China & South Korea

    • Greater China & South Korea

    • Greater China & South Korea

    • Greater China, South Korea, ASEAN countries

    • Global

    • Preclinical
    • Phase I
    • Phase II
    • Phase III / Pivotal Study
    • NDA / Regulatory Approval
    • Marketed
    • US
    • US
    • US
    • US
    • JP
    • US
    • *
    Arctic Vision China R&D Progress Partners R&D Progress

Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering from pre-clinical stage to commercial stage products. Our vision is to provide innovative therapies in China, Asia and globally to address unmet clinical needs and benefit ophthalmic patients at large. Arctic Vision is supported by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial regional and global experiences in R&D and commercialization of ophthalmic products. 

  • Eddy WuPh.D.
    Founder and CEO
  • Qing Liu M.D., Ph.D.
    Chief Medical Officer
  • York Chen M.D., EMBA
    Chief Commercial Officer
  • Simon TsangPh.D.
    Chief Business Officer
  • Ping ChengCA/CFA
    Associate Vice President, Finance
  • Jindong DingPh.D.
    Associate Vice President, Science and Research
  • Katherine HeNY Bar
    Sr. Legal Director, Legal
  • Cece HuB.S.
    Director, Corporate Development
Suite 906-908, 9F, Tower II, Century Link, 1196 Century Avenue, Shanghai, China
Copyright © 2020 Arctic Vision (Shanghai) Biotechnology Co., Ltd.